AtaiBeckley Shares at $7.17 as Lilly Agreement Sets CVR at 42 Cents

ATAI stock traded around $7.18 during July 28 dealings. Eli Lilly is offering $6.75 in cash per share and an additional contingent-value right valued up to $2.50. The premium of about $0.43 shows the market’s estimated value for the right. That figure does not represent a straightforward probability. Factors such as deal risk, tax considerations, timing, and other potential adjustments all influence the price. SEC

The total payout comes to $9.25 per share, combining cash and CVR distributions. That marks an undiscounted upside of about 29% from the current level of roughly $7.18. The cash portion is approximately 6% less than the prevailing share price. Achieving the initial $1.00 VLS-01 milestone would bring the overall value to $7.75 per share, suggesting a potential 8% gain before taxes and any discounting. The CVR will not be publicly listed or freely transferable, and it could take several years for payments to be made. SEC

VLS-01 is required to enter Phase 3 trials within four years post-closing, triggering a $1.00 payment. An additional $1.00 payment depends on U.S. approval and DEA rescheduling within seven years. For BPL-003, $0.50 is payable upon both approval and rescheduling within five years. Each milestone outcome is binary. Certain payments tied to third-party intellectual property may decrease the eventual CVR payouts. After close, Lilly’s obligation is to use commercially reasonable efforts rather than best efforts. SEC

Both firms aim to complete the deal in the third quarter of 2026. The transaction is subject to approval by holders of more than half the outstanding shares, along with antitrust, foreign-investment and other regulatory consents. The deal cannot proceed if a court or regulator blocks it. As of the most recent filings reported on July 27, there was no merger proxy or date set for a shareholder meeting. The long-stop date is January 15, 2027, with a potential extension to April 15, 2027. SEC

AtaiBeckley’s board gave unanimous approval to the merger and urges shareholders to vote in favour. Shareholder support agreements represent 56.8 million shares, or roughly 15.4% of total voting power. This forms a significant initial base. Still, winning approval requires a majority of all outstanding shares, leaving most voting power outside current agreements. The backing makes approval more likely, but by no means guaranteed. SEC

The Elumina Phase 2b study enrolled 156 participants and has completed dosing. Headline data are still anticipated in the fourth quarter of 2026. The main endpoint evaluates MADRS change on Day 29 compared to placebo. Positive results would boost the likelihood of achieving the initial $1.00 CVR milestone. Disappointing findings could cause most of the current implied CVR premium to disappear. AtaiBeckley Inc.

The Phase 2b trial assigned 193 participants with treatment-resistant depression into groups. By Day 29, those given eight milligrams showed an improvement of 12.1 points on the MADRS scale. The control group improved by 5.8 points, with a p-value of 0.0025 reported. The group that received 12 milligrams improved by 11.1 points, with a p-value of 0.0038 versus control. The FDA has granted Breakthrough Therapy designation, and Phase 3 development is under way. Management indicated that topline results from the pivotal study are expected early 2029. Approval is still uncertain. AtaiBeckley Inc.

Management indicates that its existing plans support operations, but notes that clinical expenditures might vary. As of March 31, cash and short-term investments stood at $209.9 million, representing a decrease of $10.8 million from the figure at December 31. The first quarter saw operating cash use of $21.1 million and a net loss of $29.8 million. R&D expenses amounted to $17.4 million, while general and administrative costs were $14.4 million. The company projects its funding will last into 2029, covering the scheduled BPL-003 Phase 3 data, although this is guidance rather than assurance. SEC

Under the merger agreement, AtaiBeckley is barred from actively seeking alternative offers but may review an unsolicited bid that could qualify as superior. Lilly has a window of about four business days to match improved terms. AtaiBeckley could be liable for a $104.3 million break-up fee in certain scenarios, equal to approximately 3.7% of Lilly’s $2.8 billion upfront equity value. A competing offer remains possible. SEC

The next key filing anticipated is an initial merger proxy, expected to detail the sale process, board rationale, company forecasts, and meeting schedule. Shareholders’ path to approval would become clearer once a special-meeting date is set. The merger spread could react quickly to regulatory developments or the announcement of a rival bid. There is no company-announced clinical readout set for this week. Topline results for VLS-01 are still anticipated in the fourth quarter of 2026. AtaiBeckley Inc.